{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:05:37Z","timestamp":1774566337595,"version":"3.50.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The emergence of the anti-tumor immunotherapy era has led to the widespread adoption of immune checkpoint inhibitors (ICIs) in clinical practice. While ICIs exhibit substantial anti-tumor efficacy across a broad range of malignancies, they may also induce a diverse spectrum of immune-related adverse events (irAEs), involving multiple organ systems and, in severe instances, resulting in life-threatening complications. This report describes a rare case of severe immune-mediated hepatotoxicity (IMH) in a 76-year-old male patient with postoperative gastric cancer who was undergoing adjuvant therapy with camrelizumab in combination with oxaliplatin and S-1 (SOX regimen). The condition presented as CTCAE v5.0 Grade 4 IMH and subsequently progressed to subacute liver failure (SALF). Following an inadequate response to conventional hepatoprotective agents, glucocorticoids, and immunosuppressants, the patient received artificial liver support therapy consisting of two sessions of plasma exchange (PE) and three sessions of a double plasma molecular adsorption system (DPMAS), administered in an alternating sequence. After this multimodal intervention, liver function demonstrated marked recovery and returned to normal levels four months after discharge. No tumor recurrence occurred during follow-up, and hepatic function remained stable through August 2025. This case highlights the critical need for early recognition and prompt, comprehensive management of severe ICI-related liver injury and supports the potential clinical utility of artificial liver support systems in such scenarios.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1755661","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:37:39Z","timestamp":1770964659000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Subacute liver failure caused by immunotherapy in a patient with gastric cancer was improved after multimodal treatment with artificial liver combined with liver-protective drugs: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Yueer","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfei","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2439","article-title":"Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma","volume":"24","author":"Huang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2484","article-title":"Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009","article-title":"CTCAE versi\u00f3n 5.0. Evaluaci\u00f3n de la gravedad de los eventos adversos dermatol\u00f3gicos de las terapias antineopl\u00e1sicas","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102514","article-title":"Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development","volume":"114","author":"Regev","year":"2020","journal-title":"J Autoimmun"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn501113-20230419-00176-1","article-title":"The professional committee for the prevention and treatment of drug-induced liver injury, and the drug-induced liver injury study group, chinese society of hepatology, chinese medical association, chinese guidelines for the diagnosis and treatment of drug-induced liver injury (2023)","volume":"4","year":"2023","journal-title":"Chin Guidelines Diagnosis Treat Drug-Induced Liver Injury"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101131","article-title":"Acute liver failure: A practical update","volume":"6","author":"Fern\u00e1ndez","year":"2024","journal-title":"JHEP Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"300060520932053","DOI":"10.1177\/0300060520932053","article-title":"Comparison of plasma exchange, double plasma molecular adsorption system, and their combination in treating acute-on-chronic liver failure","volume":"48","author":"Guo","year":"2020","journal-title":"J Int Med Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1007-3418.2018.10.003","article-title":"Plasma exchange combined with double plasma absorption therapy improve the prognosis of acute-on-chronic liver failure","volume":"26","author":"Zhong","year":"2018","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1001-9391.2017.01.013","article-title":"Clinical effect of combined artificial extracorporeal liver support therapy for toxic hepatic failure","volume":"35","author":"Zhou","year":"2017","journal-title":"Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn501113-20220607-00266","article-title":"Research progress of non-biological artificial liver support system therapy for paitents with liver failure","volume":"31","author":"Ma","year":"2023","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i32.5376","article-title":"Immune checkpoint inhibitor-related hepatotoxicity: A review","volume":"27","author":"Remash","year":"2021","journal-title":"World J Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332125","article-title":"Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events","volume":"74","author":"De Martin","year":"2025","journal-title":"Gut"},{"key":"B14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cpt.2022.11.003","article-title":"Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review","volume":"1","author":"Miao","year":"2023","journal-title":"Cancer Pathogenesis Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.15403\/jgld-5045","article-title":"Clinical and pathological features of immune checkpoint inhibitor-induced liver injury in comparison with drug-induced liver injury and autoimmune hepatitis","volume":"32","author":"Sunago","year":"2023","journal-title":"J Gastrointestinal Liver Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00693-7","article-title":"Standardize the diagnosis and treatment of drug-induced liver injury, and strengthen clinical and translational research","volume":"31","author":"Mao","year":"2023","journal-title":"Zhonghua gan zang bing za zhi"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13746","article-title":"Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents","volume":"38","author":"Suzman","year":"2018","journal-title":"Liver Int"},{"key":"B20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrgastro.2015.200","article-title":"Immunology in the liver \u2014 from homeostasis to disease","volume":"13","author":"Heymann","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S0140-6736(24)00693-7","article-title":"Acute liver failure","volume":"404","author":"Maiwall","year":"2024","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12629","article-title":"The mechanisms of action of plasma exchange","volume":"164","author":"Reeves","year":"2013","journal-title":"Br J Haematology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2024.102410","article-title":"Therapeutic plasma exchange in hepatology: indications, techniques, and practical application","volume":"15","author":"Agrawal","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.22926","article-title":"Effects of dual plasma molecular adsorption system on liver function, electrolytes, inflammation, and immunity in patients with chronic severe hepatitis","volume":"33","author":"Chen","year":"2019","journal-title":"J Clin Lab Anal"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1755661\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:37:42Z","timestamp":1770964662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1755661\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2026.1755661"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1755661","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"article-number":"1755661"}}